ViGenCell
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
ViGenCell develops cell-based therapies, treatments that use a patient's own or donor immune cells to fight disease, aimed at medical institutions and patients in need of advanced therapeutic options.
The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, under a special listing track reserved for technology-growth companies that have not yet reached profitability. Its Australian subsidiary was dissolved during the most recent reporting period, leaving it focused on its domestic operations.
Summary is AI-generated and may contain errors · figures from DART filings
ViGenCell was admitted to KOSDAQ under a technology-growth special listing exemption, a track that allows pre-profit biotech firms to list based on technological merit rather than financial results.
ViGenCell in five facts
What does ViGenCell do?
ViGenCell develops cell-based therapies, treatments that use a patient's own or donor immune cells to fight disease, aimed at medical institutions and patients in need of advanced therapeutic options.
Where is ViGenCell listed and in which sector?
ViGenCell (Korean name: 바이젠셀) trades under KRX code 308080 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is ViGenCell?
Its market capitalisation was US$82.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were ViGenCell's latest annual revenue and operating profit?
For fiscal year 2025, ViGenCell reported revenue of US$17.1K, an operating loss of US$12.9M and a net loss of US$12.3M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was down 91.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.